Wt 1 ablation and Igf 2 upregulation in mice result in Wilms tumors with elevated ERK 1 / 2 phosphorylation

Wilms tumor (WT) is a genetically heterogeneous childhood kidney tumor. Several genetic alterations have been identified in WT patients, including inactivating mutations in WT1 and loss of heterozygosity or loss of imprinting at 11p15, which results in biallelic expression of IGF2. However, the mechanisms by which one or a combination of genetic alterations results in tumorigenesis has remained challenging to determine, given the lack of a mouse model of WT. Here, we engineered mice to sustain mosaic, somatic ablation of Wt1 and constitutional Igf2 upregulation, mimicking a subset of human tumors. Mice with this combination of genetic alterations developed tumors at an early age. Mechanistically, Wt1 ablation blocked mesenchyme differentiation, and increased Igf2 expression upregulated ERK1/2 phosphorylation. Importantly, a subset of human tumors similarly displayed upregulation of ERK1/2 phosphorylation, which suggests ERK signaling might contribute to WT development. Thus, we have generated a biologically relevant mouse model of WT and defined one combination of driver alterations for WT. This mouse model will provide a powerful tool to study the biology of WT initiation and progression and to investigate therapeutic strategies for cancers with IGF pathway dysregulation. Technical Advance Oncology

[1]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[2]  A. McMahon,et al.  Atlas of gene expression in the developing kidney at microanatomic resolution. , 2008, Developmental cell.

[3]  A. McMahon,et al.  Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. , 2008, Cell stem cell.

[4]  Y. Arai,et al.  Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities , 2008, Genes, chromosomes & cancer.

[5]  V. Huff,et al.  Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one‐third of tumors , 2008, Genes, chromosomes & cancer.

[6]  V. Macaulay,et al.  Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer , 2008 .

[7]  P. D'Amore,et al.  IGF2: epigenetic regulation and role in development and disease. , 2008, Cytokine & growth factor reviews.

[8]  A. Feinberg,et al.  Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk , 2007, Proceedings of the National Academy of Sciences.

[9]  A. Feinberg,et al.  An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor , 2007, Science.

[10]  S. Sen,et al.  Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle , 2006, Nucleic acids research.

[11]  G. Dressler,et al.  Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney , 2006, The EMBO journal.

[12]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[13]  Fei Gao,et al.  The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis , 2006, Proceedings of the National Academy of Sciences.

[14]  R. Kooijman.  Regulation of apoptosis by insulin-like growth factor (IGF)-I. , 2006, Cytokine & growth factor reviews.

[15]  D. Housman,et al.  Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor , 2005, Nature Genetics.

[16]  A. McMahon,et al.  Distinct and sequential tissue-specific activities of the LIM-class homeobox gene Lim1 for tubular morphogenesis during kidney development , 2005, Development.

[17]  E. Batourina,et al.  Foxd1-dependent signals control cellularity in the renal capsule, a structure required for normal renal development , 2005, Development.

[18]  A. McMahon,et al.  Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. , 2005, Developmental cell.

[19]  Maria Vernucci,et al.  Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome , 2004, Nature Genetics.

[20]  H. Aburatani,et al.  Identification of kidney mesenchymal genes by a combination of microarray analysis and Sall1-GFP knockin mice , 2004, Mechanisms of Development.

[21]  N. Hastie,et al.  Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. , 2003, Human molecular genetics.

[22]  C. Laclef,et al.  Six1 is required for the early organogenesis of mammalian kidney , 2003, Development.

[23]  M. Cleary,et al.  Pbx1 regulates nephrogenesis and ureteric branching in the developing kidney. , 2003, Developmental biology.

[24]  Charles A Powell,et al.  Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. , 2002, The American journal of pathology.

[25]  M. Little,et al.  Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1 , 2002, Oncogene.

[26]  Andrew P McMahon,et al.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. , 2002, Developmental biology.

[27]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[28]  J. Davies,et al.  Erk MAP kinase regulates branching morphogenesis in the developing mouse kidney. , 2001, Development.

[29]  J. Schalken,et al.  Alterations in Expression of Cadherin–6 and E–Cadherin during Kidney Development and in Renal Cell Carcinoma , 2000, European Urology.

[30]  W. Gerald,et al.  The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin , 1999, Cell.

[31]  Joe C. Adams,et al.  Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia , 1999, Nature Genetics.

[32]  M. von Knebel Doeberitz,et al.  Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. , 1999, Cancer research.

[33]  C. Englert,et al.  The Wilms tumor suppressor gene wt1 is required for development of the spleen , 1999, Current Biology.

[34]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  V. Huff.  Wilms tumor genetics. , 1998, American journal of medical genetics.

[36]  G. Dressler,et al.  Differential expression and function of cadherin-6 during renal epithelium development. , 1998, Development.

[37]  E. Lai,et al.  Essential role of stromal mesenchyme in kidney morphogenesis revealed by targeted disruption of Winged Helix transcription factor BF-2. , 1996, Genes & development.

[38]  P. Gruss,et al.  Pax-2 controls multiple steps of urogenital development. , 1995, Development.

[39]  K. Lyons,et al.  A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. , 1995, Genes & development.

[40]  S. Tilghman,et al.  Disruption of imprinting caused by deletion of the H19 gene region in mice , 1995, Nature.

[41]  A. McMahon,et al.  Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4 , 1994, Nature.

[42]  A. Feinberg,et al.  The genetics of BWS associated tumors , 1999 .

[43]  D. Hanahan,et al.  A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.

[44]  N. Nowak,et al.  Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations , 1994, Nature Genetics.

[45]  Amy Bernard,et al.  Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour , 1993, Nature Genetics.

[46]  David Housman,et al.  WT-1 is required for early kidney development , 1993, Cell.

[47]  M. Eccles,et al.  Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour , 1993, Nature.

[48]  P. Gruss,et al.  Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system. , 1990, Development.

[49]  L. Strong,et al.  Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. , 1987, American journal of human genetics.

[50]  A. Knudson,et al.  Mutation and cancer: a model for Wilms' tumor of the kidney. , 1972, Journal of the National Cancer Institute.

[51]  C. Amos,et al.  Frequent association of beta-catenin and WT1 mutations in Wilms tumors. , 2000, Cancer research.

[52]  W. W. Nichols,et al.  Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor. , 1987, American journal of human genetics.